BR112022004272A2 - Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental - Google Patents
Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimentalInfo
- Publication number
- BR112022004272A2 BR112022004272A2 BR112022004272A BR112022004272A BR112022004272A2 BR 112022004272 A2 BR112022004272 A2 BR 112022004272A2 BR 112022004272 A BR112022004272 A BR 112022004272A BR 112022004272 A BR112022004272 A BR 112022004272A BR 112022004272 A2 BR112022004272 A2 BR 112022004272A2
- Authority
- BR
- Brazil
- Prior art keywords
- epileptic
- treatment
- developmental encephalopathy
- behavioral impairment
- encephalopathy
- Prior art date
Links
- 208000014644 Brain disease Diseases 0.000 title abstract 3
- 208000032274 Encephalopathy Diseases 0.000 title abstract 3
- 230000001037 epileptic effect Effects 0.000 title abstract 3
- 230000006736 behavioral deficit Effects 0.000 title abstract 2
- 231100000871 behavioral problem Toxicity 0.000 abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 1
- 229950011318 cannabidiol Drugs 0.000 abstract 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0077—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of chemical or pharmacological stimulus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Acoustics & Sound (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental. a presente invenção refere-se a métodos de tratamento de problemas comportamentais e ataques em um indivíduo tendo encefalopatia epiléptica e desenvolvimental (dee) através de administração transdérmica de uma quantidade efetiva de canabidiol (cbd) para o indivíduo onde problemas comportamentais são tratados no indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901651P | 2019-09-17 | 2019-09-17 | |
| PCT/US2020/051102 WO2021055499A1 (en) | 2019-09-17 | 2020-09-16 | Treatment of behavioral impairment in developmental and epileptic encephalopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022004272A2 true BR112022004272A2 (pt) | 2022-06-07 |
Family
ID=74869217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004272A BR112022004272A2 (pt) | 2019-09-17 | 2020-09-16 | Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental |
| BR112022004175A BR112022004175A2 (pt) | 2019-09-17 | 2020-09-16 | Tratamento de encefalopatia de syngap1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004175A BR112022004175A2 (pt) | 2019-09-17 | 2020-09-16 | Tratamento de encefalopatia de syngap1 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210077421A1 (pt) |
| EP (2) | EP4031119A4 (pt) |
| JP (2) | JP2022547136A (pt) |
| KR (2) | KR20220066091A (pt) |
| CN (2) | CN114401713A (pt) |
| AU (2) | AU2020350605A1 (pt) |
| BR (2) | BR112022004272A2 (pt) |
| CA (2) | CA3150617A1 (pt) |
| IL (2) | IL291363A (pt) |
| JO (2) | JOP20220054A1 (pt) |
| MX (2) | MX2022003193A (pt) |
| WO (2) | WO2021055499A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| AU2021392090A1 (en) * | 2020-12-03 | 2023-07-06 | Zynerba Pharmaceuticals, Inc. | Cannabidiol for the treatment of refractory seizures |
| MX2023008876A (es) * | 2021-01-28 | 2023-09-12 | Zynerba Pharmaceuticals Inc | Tratamiento de la apnea del sueño con cannabidiol (cbd). |
| CA3213953A1 (en) * | 2021-04-08 | 2022-10-13 | Fotios M. Plakogiannis | Pharmaceutical composition and method for treating seizure disorders |
| US20230265436A1 (en) * | 2022-02-24 | 2023-08-24 | Q-State Biosciences, Inc. | Therapeutics for syngap haploinsufficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2487712B (en) * | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2531278A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| MX2017010066A (es) * | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
| US10716766B2 (en) * | 2015-03-02 | 2020-07-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| IL246790A0 (en) * | 2016-07-14 | 2016-09-29 | Friedman Doron | Self-dissolving compounds of cannabinoids |
| IL301910A (en) * | 2017-09-19 | 2023-06-01 | Zynerba Pharmaceuticals Inc | Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults |
| WO2019089558A1 (en) * | 2017-10-30 | 2019-05-09 | Endocanna Health, Inc. | Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations |
| GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
-
2020
- 2020-09-16 EP EP20864502.8A patent/EP4031119A4/en active Pending
- 2020-09-16 JO JOP/2022/0054A patent/JOP20220054A1/ar unknown
- 2020-09-16 WO PCT/US2020/051102 patent/WO2021055499A1/en active Application Filing
- 2020-09-16 MX MX2022003193A patent/MX2022003193A/es unknown
- 2020-09-16 AU AU2020350605A patent/AU2020350605A1/en active Pending
- 2020-09-16 CN CN202080065085.5A patent/CN114401713A/zh active Pending
- 2020-09-16 BR BR112022004272A patent/BR112022004272A2/pt unknown
- 2020-09-16 KR KR1020227011640A patent/KR20220066091A/ko unknown
- 2020-09-16 BR BR112022004175A patent/BR112022004175A2/pt unknown
- 2020-09-16 JO JOP/2022/0061A patent/JOP20220061A1/ar unknown
- 2020-09-16 CA CA3150617A patent/CA3150617A1/en active Pending
- 2020-09-16 MX MX2022003194A patent/MX2022003194A/es unknown
- 2020-09-16 CN CN202080065120.3A patent/CN114423416A/zh active Pending
- 2020-09-16 AU AU2020348310A patent/AU2020348310A1/en active Pending
- 2020-09-16 JP JP2022515027A patent/JP2022547136A/ja active Pending
- 2020-09-16 US US17/022,494 patent/US20210077421A1/en active Pending
- 2020-09-16 KR KR1020227011639A patent/KR20220063208A/ko unknown
- 2020-09-16 CA CA3151171A patent/CA3151171A1/en active Pending
- 2020-09-16 EP EP20866006.8A patent/EP4031120A4/en active Pending
- 2020-09-16 WO PCT/US2020/051095 patent/WO2021055493A1/en active Application Filing
- 2020-09-16 JP JP2022515014A patent/JP2022547922A/ja active Pending
-
2022
- 2022-03-14 IL IL291363A patent/IL291363A/en unknown
- 2022-03-14 IL IL291362A patent/IL291362A/en unknown
- 2022-03-17 US US17/697,629 patent/US20220218625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4031119A4 (en) | 2023-08-02 |
| AU2020348310A1 (en) | 2022-03-31 |
| CN114423416A (zh) | 2022-04-29 |
| IL291362A (en) | 2022-05-01 |
| AU2020350605A1 (en) | 2022-03-31 |
| EP4031119A1 (en) | 2022-07-27 |
| US20220218625A1 (en) | 2022-07-14 |
| CN114401713A (zh) | 2022-04-26 |
| BR112022004175A2 (pt) | 2022-05-31 |
| JP2022547136A (ja) | 2022-11-10 |
| EP4031120A4 (en) | 2023-08-02 |
| IL291363A (en) | 2022-05-01 |
| JOP20220061A1 (ar) | 2023-01-30 |
| MX2022003194A (es) | 2022-04-11 |
| JOP20220054A1 (ar) | 2023-01-30 |
| CA3151171A1 (en) | 2021-03-25 |
| CA3150617A1 (en) | 2021-03-25 |
| EP4031120A1 (en) | 2022-07-27 |
| KR20220066091A (ko) | 2022-05-23 |
| WO2021055493A1 (en) | 2021-03-25 |
| MX2022003193A (es) | 2022-04-11 |
| US20210077421A1 (en) | 2021-03-18 |
| JP2022547922A (ja) | 2022-11-16 |
| KR20220063208A (ko) | 2022-05-17 |
| WO2021055499A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004272A2 (pt) | Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental | |
| BR112021016620A2 (pt) | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais | |
| BR112021016650A2 (pt) | Indóis substituídos por n e outros heterociclos para o tratamento de distúrbios cerebrais | |
| BR112019018093A2 (pt) | Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| BR112018012255A2 (pt) | método para tratar câncer | |
| BR112017015059A2 (pt) | inibidor de proteassoma e uso | |
| BR112018068906A2 (pt) | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo | |
| BR112017011900A2 (pt) | tratamento de ataques com fosfatase alcalina recombinante | |
| BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| BR112016028964A2 (pt) | métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação | |
| CY1125071T1 (el) | Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη | |
| BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias | |
| MX2020005547A (es) | Moduladores de la actividad del complemento. | |
| EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
| BR112018005855A2 (pt) | tratamento de doenças neurodegenerativas | |
| BR112016017886A2 (pt) | grelina ou variantes ou derivados da mesma, e, método para tratamento de uma lesão cerebral leve em um indivíduo | |
| BR112023020182A2 (pt) | Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula | |
| BR112018014762A2 (pt) | método de tratamento da doença de alzheimer (da) precoce | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| MX2023006551A (es) | Tratamiento de las convulsiones refractarias. |